Rincon Bio The Cancer Model Company Revenue and Competitors
Estimated Revenue & Valuation
- Rincon Bio The Cancer Model Company's estimated annual revenue is currently $930k per year.
- Rincon Bio The Cancer Model Company's estimated revenue per employee is $155,000
Employee Data
- Rincon Bio The Cancer Model Company has 6 Employees.
- Rincon Bio The Cancer Model Company grew their employee count by 0% last year.
Rincon Bio The Cancer Model Company's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Research Services | Reveal Email/Phone |
2 | Lab Manager | Reveal Email/Phone |
3 | Lab Manager | Reveal Email/Phone |
4 | Laboratory Associate | Reveal Email/Phone |
Rincon Bio The Cancer Model Company Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A | N/A |
#2 | $1.4M | 9 | -10% | N/A | N/A |
#3 | $5.9M | 38 | 41% | N/A | N/A |
#4 | $1.1M | 7 | -53% | N/A | N/A |
#5 | $1.6M | 10 | 11% | N/A | N/A |
#6 | $21.2M | 137 | 10% | N/A | N/A |
#7 | $1.6M | 33 | -48% | $17.8M | N/A |
#8 | $1.9M | 12 | 0% | N/A | N/A |
#9 | $3.7M | 24 | 9% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is Rincon Bio The Cancer Model Company?
Rincon Bio performs allogeneic and syngeneic xenograft studies. DOMESTIC QUALITY When you work with Rincon Bio, rest assured that all in vivo tumor studies will be high quality, and performed in the USA. COMPETITIVE PRICES Because we specialize in tumor models studies, we're able to offer highly competitive prices. SPEED TO INITIATION Most efficacy studies can be initiated within two business days.
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 6 | 0% | N/A |
#2 | $0.9M | 6 | 0% | N/A |
#3 | $0.4M | 6 | -33% | N/A |
#4 | $0.6M | 6 | 0% | N/A |
#5 | $0.4M | 6 | -14% | N/A |